Zinc finger protein ZIC 2 Antibodies

Zinc finger protein ZIC 2 (ZIC2)

Acts as a transcriptional activator or repressor. Plays important roles in the first stage of organogenesis of the CNS.

Activates the transcription of the serotonin transporter SERT in uncrossed ipsilateral retinal ganglion cells (iRGCs) to refine eye-specific projections in primary visual goals. Its transcriptional activity is repressed by MDFIC.

Gene Information

Human
Gene Name:	ZIC2
Uniprot:	O95409
Entrez:	7546

Family

Belongs to:
GLI C2H2-type zinc-finger protein family

Alternative Names

HPE5Zic family member 2 (odd-paired Drosophila homolog); Zic family member 2 (odd-paired homolog, Drosophila); Zinc finger protein of the cerebellum 2; zinc finger protein ZIC 2

Molecular Weight

Mass (kDA):
55.006 kDA

Genomic Context

Human
Location:	13q32.3
Sequence:	13; NC_000013.11 (99981784..99986765)

Subcellular Localizations

Nucleus. Cytoplasm. Localizes in the cytoplasm in presence of MDFIC overexpression. Both phosphorylated and unphosphorylated forms are localized in the nucleus (By similarity).

Diseases

• Holoprosencephaly
• Congenital Abnormality
• Crest Syndrome
• Congenital Anomaly Of Brain
• Nervousness
• Neoplasms
• Malignant Neoplasms
• Cyclocephaly
• Haploinsufficiency
• Dandy-walker Syndrome
• Cytogenetic Abnormality
• Hypoplasia
• Monosomy

• Craniofacial Abnormalities
• Congenital Absence
• Spina Bifida
• Chromosome 13q Deletion
• Microphthalmos
• Hypotelorism Of Orbit
• Cleft Lip

Pathways

• Forebrain Development
• Gastrulation
• Pathogenesis
• Neurogenesis
• Cell Proliferation
• Brain Development
• Localization
• Cell Cycle
• Neural Tube Closure
• Segmentation
• Tube Closure
• Inner Ear Development
• Dna Methylation

• Lateral Inhibition
• Methylation
• Ear Development
• Neural Crest Formation
• Transport
• Cell Cycle Checkpoint
• Developmental Process

PTMs

• Phosphorylation

• Cleavage

• Methylation

Research Areas

• Growth and Development
• Neuronal Cell Markers
• Neuroscience
• Signal Transduction
• Transcription Factors and Regulators

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ZIC2

Best Uses Of The ZIC2 Marker

The majority of biological tests detect Cnbd2 using antibodies. The protein is present in a variety of animal samples. Boster Bio has developed Cnbd2 antibodies for rabbit and mouse. This is a demonstration of the versatility and utility of this marker. Cnbd2 has several roles in the spermatogenesis process, including the regulation of the motility of sperm as well as the folding of the semen's flagellar strands.

Pan-cancer treatment using ZIC2

Researchers first searched for cancerous cells with high levels of ZIC2 to determine whether it plays a role in the development and testing of new anticancer drugs. They first identified tumors that had high levels of ZIC2 expression, and then used GSEA (Graphics-based Evaluation of All Cells) to determine KEGG pathways that were highly enriched in both populations. They discovered that ZIC2 expression in various types of cancers was significantly enhanced in a variety of tumor-related and immune-related pathways. These pathways included complement and coagulation cascades and also the P53 signaling pathway.

The gene encoding ZIC2 was amplified from MCF7 cells' cDNA and subcloned into the pCDNA3.1 plasmids. After transfection, lentiviral Supernats were collected and used to infect MCF7 cells using an empty vector. The cells were then harvested after 48 hours to determine the levels of viral particles.

These genes were examined in the study of ZIC1 (mRNA) and ZIC2(mRNA) which have a significant role to play in the expression of genes and cell growth in cancer cells. DNA methylation can be transmitted through the human genome and has been associated with the development of tumors and carcinogenesis. Particularly, ZIC2 expression correlated with the expression of six methyltransferases (MTCs).

Downregulation of ZIC2 was found in breast cancer patients, and this was associated with a lower survival rate for patients. ZIC2 deregulation was associated with poor survival among breast cancer patients and could be an independent prognostic marker. The cancer-causing effects of reduced ZIC2 expression were counteracted by inhibition of STAT3. This could provide an alternative treatment option for women who have low ZIC2 expression levels.

ZIC2 was first identified as an oncogene in the common ancestor of all animals. Its overexpression is connected to the expression of other cancer genes. The overexpression of ZIC2 is linked to the expression of 13 other genes. ZIC2 expression can help identify pan-cancer as well as other cancers. Therefore, it is crucial to know how ZIC2 regulates gene expression in order to determine which genes are responsible for causing cancer.

Correlation between ZIC2 expression and TMB, MSL, and the microenvironment that protects the tumor.

In 34 different cancer samples, we discovered strong correlations between ZIC2 expression, TMB, MSL and the tumor immune microenvironment. We have found a link between ZIC2 expression and the immune cells, DNAmethyltransferases, and the MMRs immune control point. We also discovered a link between ZIC2 expression and mRNA m6A expression. These results suggest that ZIC2 may be used as a diagnostic and prognostic marker for kidney cancer.

IL2RB plays a significant role in the immune system because it helps to ensure the survival of cells and encourages the development of chemoresistance. We analyzed its relation to TMB, MSL, and tumor immune microenvironment using Estimate in the R package and IL2RB. MSI and IL2RB were positively related. BLCA and CESC were the most closely related cancers.

Furthermore, the study showed a strong relationship between IL2RB expression and prognosis for pan-cancer. It also found a relationship between the IL2RB transcript content and the tumor immune microenvironment. IL2RB expression was significantly elevated in 21 of 27 tumor tissues when compared to non-tumorous counterparts.

Although ZIC2 may play a role in the immune response however, we have not found any evidence that suggests it improves the patient survival in cancer. These findings suggest that ZIC2 could be a biomarker of pan-cancer. The study also demonstrated that ZIC2 was found to be enriched in immune and tumor-related pathways. It is important to keep in mind that we haven't yet investigated the role of ZIC2 in pan-cancer cells. Therefore, we are unable to determine if it is a reliable prognostic factor for this disease.

While TMB is not positively associated with CD8+ T cells, TMB negatively correlates with the immune score in the study. However, it negatively correlates with the score of the immune system in TGCT. In the malignant transformations of papillary and thyroid cancer, CAF isn't fully understood. For this reason, this study examined the relationship between CAF and tumor immune microenvironment.

These studies also showed a strong association between ZIC2 and five methyltransferases. Furthermore, this study confirms the potential role of ZIC2 in the development of tumors as well as carcinogenesis of cells. The study also demonstrates that ZIC2 regulates various genes associated with the immune system. It is crucial to recognize that m6A (6-methyladenine) methylation may be an important oncogenic driver in human cancer.

Relationship between ZIC2 expression and tumor prognosis

The relationship between ZIC2 expression and tumor prognoses was studied using gene chip data from TCGA and GEO. We then performed gene expression profile interaction analysis (GEPIA) to establish the connection between ZIC2 expression and prognosis. We also utilized the Genecards database for ZIC2-related proteins. We also studied the connection between ZIC2's expression of mRNA and immune microenvironment infiltration.

Our findings show that the expression of ZIC2 gene was significantly associated with immune cell invasion and poor prognosis among patients suffering from liver cancer. Furthermore, our findings suggest that ZIC2 could be a potential biomarker for immunotherapy for liver cancer. In the future, these findings may help healthcare professionals determine the best treatment for patients. However, more research is needed to determine whether ZIC2 gene expression is linked in the prognosis of patients.

A number of studies have been done using cell lines transfected by Axin2 or Zic2. We measured luciferase reporter activities in DLD-1 cells, HCT116 cells, SW480, and axin2 cell lines. We also utilized Western blotting to assess the changes in mRNA levels and gene expression of Zic2 in cell lines. These data help us better comprehend the relationship between ZIC2 and tumor prognosis.

The connection between ZIC2 expression and cancer prognoses is not yet studied extensively in pan-cancer. This gene has been implicated for cancers with ERG-fusion. Therefore, it is essential to develop new methods for investigating the role played by ZIC2 in predicting the prognosis of tumors. The study also suggests ZIC2 is a new biomarker which could be useful in predicting tumor progression.

In a recent study researchers have discovered that the expression of ZIC2 is linked to a lower survival in various cancers. Researchers found that patients with Hepatocellular cancer had lower OS and survival rates because of high levels of ZIC2. In addition, high levels of ZIC2 in lung cancer patients predicted a lower OS than patients with lower expression. These findings support the notion of ZIC2 being a biomarker that is early for breast cancer.

Potential therapeutic target

A commonly marker that is methylated is ZIC2 which has been linked with cancer in humans. ZIC2 has been shown influence the DNA modification m6A. Many methyltransferases are involved in ZIC2 expression and these genes were found to have significant inverse relationships with ZIC2 expression. These results suggest that ZIC2 could act as an oncogenic trigger for human cancer.

Recent research has shown that ZIC2 is associated with a poor prognosis among cancer cells. This biomarker can be used as a diagnostic and diagnostic marker. It is found in every type of pathological cancer. Furthermore, researchers are conducting research with cell lines that carry this gene to discover the way ZIC2 expression can affect the prognosis for a patient. ZIC2 is thus considered possibly a therapeutic and diagnostic target.

Although it's not entirely specific what Zic2 does in colon cancer, there are many indications that this gene should be targeted. Patients' outcomes have been shown to be poor. related to the reduction of Zic2 expression in colon cancer cells. For instance, a lack of Zic2 in colon cancer cells renders them more resistant to apoptosis in response to low-glucose. Additionally, Zic2 can regulate the creation of tumor spheres as well as impede the growth rate of xenografts.

A variety of studies have also shown that Zic2 is a key regulator of Wnt/b-catenin signaling. In one study, Zic2 directly binds the Axin2 promoter and suppresses Axin2 expression, which in turn promotes nuclear translocation and accumulation of b-catenin. It has been shown that a mutation in Zic2 can hinder CK1 phosphorylation.